For how we live.
The phase 3 CLL6 RESIDUUM trial extended progression-free survival by about 22 months in patients left with residual disease, but overall survival did not differ and the drug caused more infections.
In the single-arm EPCORE NHL-2 cohort, adding epcoritamab to rituximab and lenalidomide produced responses in 95% of 41 untreated follicular lymphoma patients, with no control group to prove added benefit.
In the MajesTEC-9 trial, the bispecific antibody teclistamab cut the risk of progression or death by 71% against standard three- and two-drug regimens. Serious infections were common.